Ondine Biomedical, a Canadian company specializing in life sciences, has declared that it is stepping up the final preparations to kick off its key US Phase 3 clinical trial in Q4 2024. This acceleration comes in the wake of a successful fundraiser that totalled Cdn $16 million (US $11m), attracting substantial support from existing institutional…